Every 8-K that Kestra Medical Technologies, Ltd. (KMTS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KMTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KMTS filings page.
Kestra Medical Technologies, Ltd. (KMTS) reported first quarter fiscal 2027 results for the period ended July 31, 2026, highlighted by rapid top-line growth but widening losses. Revenue reached $31.0 million, a 60% increase from $19.4 million a year earlier, driven by wearable cardioverter defibrillator market expansion, competitive share gains, new territories, a higher mix of in-network patients, and better revenue cycle management.
Gross profit rose to $17.5 million, with gross margin expanding to 56.5% from 45.7% on volume leverage, more in-network patients, and cost improvements. GAAP operating expenses increased to $55.2 million from $37.7 million, and GAAP net loss widened to $44.1 million from $25.8 million. Adjusted EBITDA loss was $24.0 million, compared with a $19.4 million loss. Kestra ended the quarter with $244.7 million in cash, cash equivalents and investments and reported total liquidity of approximately $320 million, including committed unused term loan availability. The company raised FY27 revenue guidance to $141 million, implying 48% growth versus FY26 and up from prior guidance of $137 million.
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported the results of its 2026 annual general meeting of shareholders held on September 9, 2026. A total of 55,399,491 common shares were voted in person or by proxy, representing 94.53% of the 58,603,121 shares outstanding and entitled to vote as of July 17, 2026.
Shareholders elected Class II directors Raymond W. Cohen, Kevin Reilly, and Traci S. Umberger to serve until the 2029 annual meeting and until their successors are duly elected and qualified. Shareholders also ratified PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending April 30, 2027.
Kestra Medical Technologies, Ltd. entered into a five-year senior secured term loan facility of up to $200.0 million with funds managed by Pharmakon Advisors. Tranche A of $75.0 million funded on July 10, 2026, generating approximately $20.0 million of net proceeds after fees and full repayment of the prior Perceptive Credit loan, which was terminated and its security interests released.
The Term Loans mature on July 10, 2031, bear interest at three-month SOFR + 5.50% with a 3.25% SOFR floor, include 48 months of interest-only payments, and then amortize quarterly from the second fiscal quarter of 2030. Covenants include minimum liquidity of at least $20.0 million, limits on additional indebtedness, liens, dividends and mergers, and a security interest over substantially all assets, including intellectual property.
For the quarter ended April 30, 2026, revenue was $28.6 million, up 66% year over year, with gross margin of 54.8%. Fiscal 2026 revenue was $95.1 million, up 59%, with gross margin of 51.4%. GAAP net loss was $131.6 million and adjusted EBITDA loss was $87.0 million. Cash, cash equivalents and investments totaled $262.2 million as of April 30, 2026. The company guides to FY27 revenue of $137 million, implying 44% growth versus FY26.
Kestra Medical Technologies reported strong growth for its third fiscal quarter ended January 31, 2026. Revenue reached $24.6 million, up 63% from the prior-year period, driven by higher ASSURE system prescriptions, market share gains and a richer mix of in-network patients.
Gross margin improved to 52.6% from 43.4%, but GAAP net loss widened to $34.2 million from $21.8 million as operating expenses rose with commercial expansion and public company costs. Adjusted EBITDA loss was $21.2 million. Cash and cash equivalents were $291 million as of January 31, 2026, reflecting proceeds from a 6.9 million-share equity offering. The company raised its fiscal 2026 revenue guidance to $93 million, implying 55% growth versus fiscal 2025.
Kestra Medical Technologies, Ltd. filed a current report stating that it issued a press release announcing its financial results for the fiscal quarter ended October 31, 2025.
The press release, dated December 11, 2025, is attached as Exhibit 99.1, is incorporated by reference into this report, and is furnished rather than filed, so it is not automatically incorporated into other securities filings unless specifically referenced.
Kestra Medical Technologies (KMTS) filed an 8‑K under Regulation FD, furnishing a press release titled “Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device.” The release announces primary results from the ACE‑PAS post‑approval study, presented as late‑breaking science at the American Heart Association Scientific Sessions 2025 in New Orleans.
The press release is furnished as Exhibit 99.1 and, as noted, is not deemed “filed” for Section 18 liability purposes or incorporated by reference unless specifically stated. The filing includes customary forward‑looking statements language and directs readers to risk factors in the company’s Form 10‑K for the fiscal year ended April 30, 2025.
Kestra Medical Technologies, Ltd. furnished an update on its recent performance by announcing that it issued a press release with financial results for the fiscal quarter ended July 31, 2025. The company reported these quarterly results through a press release dated September 11, 2025, which is attached as an exhibit to this report.
The press release is provided for informational purposes and is designated as “furnished” rather than “filed,” meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
Kestra Medical Technologies, Ltd. held its 2025 annual general meeting of shareholders on September 3, 2025. A total of 48,835,102 common shares were voted in person or by proxy, representing approximately 95% of the 51,348,656 shares outstanding and entitled to vote as of July 7, 2025.
Shareholders elected Conor Hanley and Elizabeth Kwo as Class I directors to serve until the 2028 annual meeting and until their successors are duly elected and qualified. The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending April 30, 2026 was ratified. Shareholders also approved the company’s 2025 Employee Stock Purchase Plan.